Literature DB >> 15902861

Periprosthetic bone remodeling around a prosthesis for distal femoral tumors: longitudinal follow-up.

Aileen M Davis1, Mansour Damani, Lawrence M White, Jay S Wunder, Anthony M Griffin, Robert S Bell.   

Abstract

Serial measurements using dual-energy x-ray absorptiometry (DEXA) were undertaken to evaluate progressive periprosthetic bone loss in patients treated for primary bone tumors of the distal femur using an uncemented tumor prosthesis. Twelve patients underwent sequential DEXA analysis on average 26.5 and 90.9 months postsurgery. Changes in bone mineral density were measured in regions of interest (ROIs) around the prosthesis stem. The test-retest reliability coefficient (r) ranged from 0.92 to 0.99 for all ROI. In the most distal ROI (ROI1), 10 of 11 patients with 2 measurements showed no change or a small increase in absolute bone mineral density. The results in other ROIs were similar. This longitudinal DEXA data suggest that progressive bone resorption is not problematic with an uncemented distal femur endoprosthesis at intermediate follow-up. Key words: DEXA, stress shielding, uncemented endoprothesis, tumor, bone loss.

Entities:  

Mesh:

Year:  2005        PMID: 15902861     DOI: 10.1016/j.arth.2004.10.009

Source DB:  PubMed          Journal:  J Arthroplasty        ISSN: 0883-5403            Impact factor:   4.757


  2 in total

1.  Extremity sarcoma surgery in younger children: ten years of patients ten years and under.

Authors:  Ryan B Israelsen; Benjamin E Illum; Susie Crabtree; R Lor Randall; Kevin B Jones
Journal:  Iowa Orthop J       Date:  2011

2.  What is the Cumulative Incidence of Revision Surgery and What Are the Complications Associated With Stemmed Cementless Nonextendable Endoprostheses in Patients 18 Years or Younger With Primary Bone Sarcomas About the Knee.

Authors:  Ahmed Mohamed El Ghoneimy; Amin Mohamed Shehab; Nesma Farid
Journal:  Clin Orthop Relat Res       Date:  2022-02-16       Impact factor: 4.755

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.